Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7991881 | 1.00 | SLC6A4 (0.47) | SLC6A4EPHX1TAAR1SLC6A2CYP1A2 | |
| SCHEMBL21676634 | 1.00 | SLC6A4 (0.47) | SLC6A4EPHX1TAAR1SLC6A2CYP1A2 | |
| SCHEMBL11068499 | 0.88 | SLC6A4 (0.58) | SLC6A4EPHX1TAAR1CYP1A2CYP2A6 | |
| SCHEMBL31166260 | 0.82 | SLC6A4 (0.62) | SLC6A4EPHX1TAAR1CYP1A2CYP2A6 | |
| SCHEMBL9922125 | 0.82 | TAAR1 (0.48) | SLC6A4EPHX1TAAR1CYP1A2CYP2A6 | |
| SCHEMBL28789467 | 0.82 | TAAR1 (0.48) | SLC6A4EPHX1TAAR1CYP1A2CYP2A6 | |
| SCHEMBL13323447 | 0.82 | SLC6A4 (0.62) | SLC6A4EPHX1TAAR1CYP1A2CYP2A6 | |
| SCHEMBL3127917 | 0.80 | SLC6A4 (0.45) | SLC6A4EPHX1TAAR1SLC6A2CYP1A2 | |
| SCHEMBL19062573 | 0.80 | SLC6A4 (0.45) | SLC6A4EPHX1TAAR1CYP1A2CYP2A6 | |
| SCHEMBL21887998 | 0.79 | MMP2 (0.44) | SLC6A4EPHX1TAAR1SLC6A2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174685-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-30 | — | — | US | disclosed |
| US-11905297-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | MOLECURE S.A. (PL) | 2023-05-02 | — | — | US | disclosed |
| US-20230122024-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-20 | — | — | US | disclosed |
| US-11479560-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-10-25 | — | — | US | disclosed |
| US-11472813-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-18 | — | — | US | disclosed |
| US-20210163494-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210107914-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3773566-A1 | OX2R COMPOUNDS | Board of Regents, The University of Texas System (US) | 2021-02-17 | — | — | EP | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2012-01-19 | — | — | US | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015909-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | SLC6A4 467/4885EPHX1 629/4885TAAR1 195/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | SLC6A4 4659/4885EPHX1 869/4885TAAR1 2358/4885 |
| US-11479560-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | SLC6A4 2627/4885EPHX1 2125/4885TAAR1 187/4885 |
| US-11905297-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | SLC6A4 2627/4885EPHX1 2125/4885TAAR1 187/4885 |
| US-20240174685-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | SLC6A4 2627/4885EPHX1 2125/4885TAAR1 187/4885 |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | SLC6A4 4724/4885EPHX1 2668/4885TAAR1 4382/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | SLC6A4 4659/4885EPHX1 869/4885TAAR1 2358/4885 |
| US-20210107914-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | SLC6A4 2627/4885EPHX1 2125/4885TAAR1 187/4885 |
| US-20230122024-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | SLC6A4 2627/4885EPHX1 2125/4885TAAR1 187/4885 |
| US-11472813-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | SLC6A4 2627/4885EPHX1 2125/4885TAAR1 187/4885 |
| US-11638707-B2 | Substituted amino triazoles useful as chitinase inhibitors | CHIT1, CHIA, CHI3L1 | SLC6A4 3932/4885EPHX1 1072/4885TAAR1 1789/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | SLC6A4 4659/4885EPHX1 869/4885TAAR1 2358/4885 |
| US-20210163494-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | SLC6A4 2627/4885EPHX1 2125/4885TAAR1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.